Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study

INTRODUCTION: STRIVE was a 4-year, multicenter, observational, open-label, single-arm study of natalizumab treatment in anti-JC virus antibody-negative (JCV-negative) relapsing-remitting multiple sclerosis (RRMS) patients with disease duration ≤ 3 years. The objective of STRIVE was to examine no evi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Adv Ther
Hoofdauteurs: Perumal, Jai, Balabanov, Roumen, Su, Ray, Chang, Roger, Balcer, Laura, Galetta, Steven, Campagnolo, Denise I., Avila, Robin, Lee, Lily, Rutledge, Danette, Fox, Robert J.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer Healthcare 2021
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8279996/
https://ncbi.nlm.nih.gov/pubmed/34014549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01722-w
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items